Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.

Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P, Yao M.

Am J Otolaryngol. 2018 Sep - Oct;39(5):642-645. doi: 10.1016/j.amjoto.2018.06.003. Epub 2018 Jun 5.

PMID:
29903623
2.

Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.

Yoon H, Karapetyan L, Choudhary A, Kosozi R, Bali GS, Zaidi AH, Atasoy A, Forastiere AA, Gibson MK.

Oncologist. 2018 Sep;23(9):1004-e102. doi: 10.1634/theoncologist.2017-0657. Epub 2018 May 16.

PMID:
29769385
3.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

4.

Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy.

Okoye CC, Bucher J, Tatsuoka C, Parikh SA, Oliveira GH, Gibson MK, Machtay M, Yao M, Zender CA, Dorth JA.

Head Neck. 2017 Mar;39(3):527-532. doi: 10.1002/hed.24646. Epub 2016 Dec 29.

5.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
6.

A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes.

Davison JM, Landau MS, Luketich JD, McGrath KM, Foxwell TJ, Landsittel DP, Gibson MK, Nason KS.

Clin Gastroenterol Hepatol. 2016 Mar;14(3):369-377.e3. doi: 10.1016/j.cgh.2015.10.020. Epub 2015 Oct 26.

7.

The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma.

Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS.

Am J Surg. 2015 Oct;210(4):610-7. doi: 10.1016/j.amjsurg.2015.05.010. Epub 2015 Jun 26.

8.

A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri U, Kim S, Johnson JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):480-8. doi: 10.1016/j.ijrobp.2014.11.023. Epub 2015 Jan 30.

PMID:
25680594
9.

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.

Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS.

J Thorac Cardiovasc Surg. 2015 Feb;149(2):538-47. doi: 10.1016/j.jtcvs.2014.10.044. Epub 2014 Oct 14.

10.

A rare case of malignant glomus tumor of the esophagus.

Bali GS, Hartman DJ, Haight JB, Gibson MK.

Case Rep Oncol Med. 2013;2013:287078. doi: 10.1155/2013/287078. Epub 2013 Dec 17.

11.

MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.

Davison JM, Ellis ST, Foxwell TJ, Luketich JD, Gibson MK, Kuan SF, Nason KS.

Hum Pathol. 2014 Mar;45(3):540-8. doi: 10.1016/j.humpath.2013.10.020. Epub 2013 Oct 30.

12.

Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.

Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, Davison JM, R C, Irvin, Hoppo T, Nason KS, Kelly LA, Gibson MK, Jobe BA.

PLoS One. 2013 Nov 4;8(11):e78343. doi: 10.1371/journal.pone.0078343. eCollection 2013.

13.

Barrett's esophagus: cancer and molecular biology.

Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Räsänen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ, Farrant JM, Tosh D, Das KM, Bajpai M.

Ann N Y Acad Sci. 2013 Oct;1300:296-314. doi: 10.1111/nyas.12252. Review.

PMID:
24117650
14.

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N.

J Surg Oncol. 2013 Sep;108(4):236-41. doi: 10.1002/jso.23392.

15.

Oesophageal carcinoma.

Pennathur A, Gibson MK, Jobe BA, Luketich JD.

Lancet. 2013 Feb 2;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6. Review.

16.

Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.

Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA.

Ann Surg. 2013 Jul;258(1):82-8. doi: 10.1097/SLA.0b013e318270500d.

PMID:
23108119
17.

The role of cetuximab in the management of head and neck cancers.

Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK.

Expert Opin Biol Ther. 2012 Apr;12(4):517-28. doi: 10.1517/14712598.2012.667397. Review.

PMID:
22413826
18.

Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.

Defoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS.

Am J Clin Oncol. 2011 Dec;34(6):587-92. doi: 10.1097/COC.0b013e3181f942af.

PMID:
22101387
19.

Barrett's esophagus and animal models.

Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, Oyama K, Miyashita T, Ohta T, Miwa K, Gibson MK, Zaidi A, Malhotra U, Atasoy A, Foxwell T, Jobe B.

Ann N Y Acad Sci. 2011 Sep;1232:392-400. doi: 10.1111/j.1749-6632.2011.06061.x.

20.

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.

Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK.

BMC Cancer. 2011 May 17;11:176. doi: 10.1186/1471-2407-11-176.

Supplemental Content

Loading ...
Support Center